Clinical Trial Update: Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 [Phase 3]

View source ↗

Summary

A Phase 3 extension study evaluating adjuvant treatment after neoadjuvant therapy and surgery in HER2-positive early-stage breast cancer has completed enrollmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Stage Iiia Breast Cancer

Drugs mentioned

• Not specified in provided information

Snippet

Sponsor: Tanvex BioPharma USA, Inc. | Conditions: HER2-positive Breast Cancer, Early-stage Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2022-10-26